Indonesia : Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

Sovereign Project | 54425-001

The project will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX), and will provide Bio Farma with financing for vaccine procurement and logistics based on an agreed list of eligible expenditures to vaccinate priority populations against the coronavirus disease (COVID-19). The project is aligned with the following operational priorities of Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. The project is consistent with the Asian Development Bank country partnership strategy for Indonesia, 2020-2024, as it will improve the well-being of Indonesians by strengthening the health system and preventing the spread of COVID-19.

Project Details

  • Project Officer
    Qari, Amr J.
    Southeast Asia Department
    Request for information
  • Approval Date
    31 March 2021
  • Country/Economy
    Indonesia
  • Sector
    • Health
Project Name Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Project Number 54425-001
Country / Economy Indonesia
Project Status Approved
Project Type / Modality of Assistance Loan
Source of Funding / Amount
Loan 4058-INO: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Ordinary capital resources US$ 450.00 million
Strategic Agendas Inclusive economic growth
Regional integration
Drivers of Change Gender Equity and Mainstreaming
Knowledge solutions
Sector / Subsector

Health / Disease control of communicable disease
Gender Some gender elements
Description The project will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX), and will provide Bio Farma with financing for vaccine procurement and logistics based on an agreed list of eligible expenditures to vaccinate priority populations against the coronavirus disease (COVID-19). The project is aligned with the following operational priorities of Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. The project is consistent with the Asian Development Bank country partnership strategy for Indonesia, 2020-2024, as it will improve the well-being of Indonesians by strengthening the health system and preventing the spread of COVID-19.
Project Rationale and Linkage to Country/Regional Strategy COVID-19 continues to spread widely in Indonesia, with more than 1.3 million people infected and about 35,000 fatalities as of early March 2021. In February 2021, the daily positivity rate (the percentage of individuals who tested positive out of the total number of individuals tested) stood at over 20% which is significantly higher than the 5% benchmark set by the World Health Organization. Surveillance systems and volunteers have been deployed to carry out contact tracing, but there remains a wide gap between the number suspected and tested.
Impact

Transmission of COVID-19 reduced, public health improved, and economic productivity restored

SARS-CoV-2's spread, morbidity, and mortality reduced, and confidence of citizens restored
Project Outcome
Description of Outcome

Priority populations vaccinated against COVID-19
Progress Toward Outcome
Implementation Progress
Description of Project Outputs

COVID-19 vaccines procured and deployed to provinces
Status of Implementation Progress (Outputs, Activities, and Issues)
Geographical Location Nation-wide
Safeguard Categories
Environment C
Involuntary Resettlement C
Indigenous Peoples C
Summary of Environmental and Social Aspects
Environmental Aspects
Involuntary Resettlement
Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
During Project Design
During Project Implementation
Business Opportunities
Consulting Services Not applicable. No consulting service required.
Procurement Multiple contracts for purchase of eligible vaccines through direct contracting will be financed in full or in part by up to $445.27 million of the loan proceeds.
Responsible ADB Officer Qari, Amr J.
Responsible ADB Department Southeast Asia Department
Responsible ADB Division Human and Social Development Division, SERD
Executing Agencies
PT Bio Farma
Timetable
Concept Clearance 30 Nov 2020
Fact Finding 16 Nov 2020 to 22 Jan 2021
MRM 10 Feb 2021
Approval 31 Mar 2021
Last Review Mission -
Last PDS Update 06 Apr 2021

Project Data Sheets (PDS) contain summary information on the project or program. Because the PDS is a work in progress, some information may not be included in its initial version but will be added as it becomes available. Information about proposed projects is tentative and indicative.

The Access to Information Policy (AIP) recognizes that transparency and accountability are essential to development effectiveness. It establishes the disclosure requirements for documents and information ADB produces or requires to be produced.

The Accountability Mechanism provides a forum where people adversely affected by ADB-assisted projects can voice and seek solutions to their problems and report alleged noncompliance of ADB's operational policies and procedures.

In preparing any country program or strategy, financing any project, or by making any designation of, or reference to, a particular territory or geographic area in this document, the Asian Development Bank does not intend to make any judgments as to the legal or other status of any territory or area.

Safeguard Documents See also: Safeguards
Safeguard documents provided at the time of project/facility approval may also be found in the list of linked documents provided with the Report and Recommendation of the President.

Title Document Type Document Date
Asia Pacific Vaccine Access Facility for Responsive COVID-19 Vaccines for Recovery: Initial Environmental Examination Initial Environmental Examination Jan 2021

Evaluation Documents See also: Independent Evaluation

None currently available.

Related Publications

None currently available.

The Access to Information Policy (AIP) establishes the disclosure requirements for documents and information ADB produces or requires to be produced in its operations to facilitate stakeholder participation in ADB's decision-making. For more information, refer to the Safeguard Policy Statement, Operations Manual F1, and Operations Manual L3.

Requests for information may also be directed to the InfoUnit.

Tenders

No tenders for this project were found.

Contracts Awarded

No contracts awarded for this project were found

Procurement Plan

Title Document Type Document Date
Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility: Procurement Plan Procurement Plans Mar 2021